| Stereochemistry | ABSOLUTE |
| Molecular Formula | 2C11H23N2OS.O.V |
| Molecular Weight | 529.697 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | -4 |
SHOW SMILES / InChI
SMILES
[O--].[V].CCCCCCCCNC(=O)[C@@H](N)C[S-].CCCCCCCCNC(=O)[C@@H](N)C[S-]
InChI
InChIKey=PTNIVTYIODVYLK-XFMZQWNHSA-L
InChI=1S/2C11H24N2OS.O.V/c2*1-2-3-4-5-6-7-8-13-11(14)10(12)9-15;;/h2*10,15H,2-9,12H2,1H3,(H,13,14);;/q;;-2;/p-2/t2*10-;;/m00../s1
| Molecular Formula | V |
| Molecular Weight | 50.9415 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C11H24N2OS |
| Molecular Weight | 232.386 |
| Charge | 0 |
| Count |
MOL RATIO
2 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | HO |
| Molecular Weight | 17.0073 |
| Charge | -1 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Naglivan [PMD 501, vanadeine] is a vanadyl organometallic agent, in the preclinical phase of development in France, with Pan Medica, as an orally-active drug for the treatment of diabetes mellitus. Naglivan is an orally effective form of vanadyl with an oral potency 7.6 times greater than that of vanadyl sulfate (minimum effective dose: 0.06 mmol vanadium.kg-1.day-1) as compared to vanadyl sulfate (0.46 mmol vanadium.kg-1.day-1). The lack of incidence of diarrhea in either control or diabetic animals demonstrates that naglivan could be a more therapeutically desirable form of vanadyl.
Originator
Approval Year
PubMed
Sample Use Guides
The antidiabetic effects of naglivan in rats made diabetic with streptozotocin (55 mg/kg, i.v.) were tested. Four days after the streptozotocin injection, one diabetic group (DVI) and a control group (CV) were treated with naglivan (50 mg/kg/day, equivalent to 0.06 mmol vanadium/kg/day) by oral gavage.
Route of Administration:
Oral
